Breaking News

Kemwell’s Bengaluru Facility Completes U.S. FDA Inspection

This demonstrates the company’s ability to meet cGMP and aseptic drug-product manufacturing standards.

By: Rachel Klemovitch

Assistant Editor

Kemwell Biopharma (Kemwell), a global biologics Contract Development and Manufacturing Organization (CDMO), announced that its drug-product manufacturing facility in Bengaluru has completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. The inspection was conducted as part of a Pre-Approval Inspection (PAI) following the transfer of product technology f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters